• Explore /
  • Poster
  • / Extension of overall survival (OS) beyond objective responses (OR) in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with high dose interleukin-2 (HD IL-2).

Extension of overall survival (OS) beyond objective responses (OR) in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with high dose interleukin-2 (HD IL-2).

Abstract Poster

Authors

null

David D. Stenehjem

Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT

David D. Stenehjem , Michael Toole , Joseph Merriman , Kinjal Parikh , Stephanie Daignault , Sarah Scarlett , Peg Esper , Katherine Skinner , Aaron Udager , Srinivas Kiran Tantravahi , Alli M. Straubhar , Archana M. Agarwal , Joan Van Atta , Kenneth F. Grossmann , Wolfram E. Samlowski , Bruce G. Redman , Neeraj Agarwal , Ajjai Shivaram Alva

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer

Sub Track

Kidney Cancer

Citation

J Clin Oncol 33, 2015 (suppl; abstr 4565)

DOI

10.1200/jco.2015.33.15_suppl.4565

Abstract #

4565

Poster Bd #

239

Abstract Disclosures

Similar Posters

First Author: Joseph Merriman

First Author: Suzanne Phillips

First Author: Joseph Clark

First Author: Giuseppe Procopio